Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Aul

Showing results (161-170 of 177) with videos related to

Pageof 18
Sort By:
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Blood|October 6, 2001
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDST de Witte, S Suciu, G Verhoef, et al.
Leukemia|May 17, 2003
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)M Oosterveld, S Suciu, G Verhoef, et al.
Leukemia|September 11, 2009
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGE Lengfelder, C Haferlach, S Saussele, et al.
Leukemia|August 15, 2000
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative GroupE Lengfelder, A Reichert, C Schoch, et al.
International Journal of Hematology|February 24, 2001
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?T Büchner, W Hiddemann, B Wörmann, et al.
Annals of Hematology|May 6, 2004
Subgroup specific therapy effects in AML: AMLCG dataTh Büchner, W Hiddemann, W E Berdel, et al.
Leukemia|June 22, 2013
Monosomal karyotype in MDS: explaining the poor prognosis?J Schanz, H Tüchler, F Solé, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2001
Remission induction therapy: the more intensive the better?T Büchner, W Hiddemann, W Berdel, et al.
Leukemia|January 23, 2024
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classificationK Nachtkamp, C Strupp, M Vukelja, et al.
Pageof 18

Showing results (161-170 of 177) with videos related to

Sort By:
Pageof 18
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Blood|October 6, 2001
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDST de Witte, S Suciu, G Verhoef, et al.
Leukemia|May 17, 2003
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)M Oosterveld, S Suciu, G Verhoef, et al.
Leukemia|September 11, 2009
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGE Lengfelder, C Haferlach, S Saussele, et al.
Leukemia|August 15, 2000
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative GroupE Lengfelder, A Reichert, C Schoch, et al.
International Journal of Hematology|February 24, 2001
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?T Büchner, W Hiddemann, B Wörmann, et al.
Annals of Hematology|May 6, 2004
Subgroup specific therapy effects in AML: AMLCG dataTh Büchner, W Hiddemann, W E Berdel, et al.
Leukemia|June 22, 2013
Monosomal karyotype in MDS: explaining the poor prognosis?J Schanz, H Tüchler, F Solé, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2001
Remission induction therapy: the more intensive the better?T Büchner, W Hiddemann, W Berdel, et al.
Leukemia|January 23, 2024
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classificationK Nachtkamp, C Strupp, M Vukelja, et al.
Pageof 18